Internal Reference Number: FOI_6768
Date Request Received: 07/09/2022 00:00:00
Date Request Replied To: 13/09/2022 00:00:00
This response was sent via: By Email
Request Summary: Usage of biologic and biosimilar products by Rheumatology Department
Request Category: Companies
| Question Number 1: Could you provide the numbers of patients treated by the Rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] | |
| Answer To Question 1: abatacept 43 adalimumab (Humira) 26 adalimumab (biosimilars) 247 apremilast 7 baricitinib 71 certolizumab 41 etanercept (Enbrel) 10 etanercept (biosimilars) 118 filgotinib 21 golimumab 21 guselkumab <5 infliximab (Remicade) 6 infliximab (biosimilars) 22 ixekizumab 30 risankizumab 0 rituxumab (Mabthera) 0 rituximab (biosimilars) 23 sarilumab <5 secukinumab 18 tocilizumab 41 tofacitinib 30 upadacitinib 37 ustekinumab <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
